SNWV — SANUWAVE Health, Inc.

Summary of SANUWAVE (SNWV) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $13.4 million, a 30% increase year-over-year.
• Full Year Revenue: $44.1 million, up 35% from 2024.
• Adjusted EBITDA: $4.8 million in Q4, compared to $3.7 million in the prior year; full year adjusted EBITDA rose to $13.6 million, an 89% increase.
• Gross Margin: 74.7% for Q4, down 320 basis points year-over-year, primarily due to a $486,000 inventory write-off related to discontinued products.
• Net Income: $7.7 million, a significant recovery from a net loss of $13.3 million in Q4 2024, largely due to a change in fair value of derivative liabilities.
• Active Systems: 1,292 active UltraMIST systems at the end of Q4, a 5% increase from Q3, despite 168 systems being discontinued.

2. Strategic Updates and Business Highlights

• Product Transition: The company discontinued the dermaPACE and Profile product lines in Q4 to focus on UltraMIST.
• Sales Strategy: Increased engagement with resellers and distributors, which accounted for 32% of Q4 revenues, up from 26% in Q3.
• New Customer Base: Emergence of new mobile wound care providers ("baby elephants") as existing providers face challenges, creating opportunities for SANUWAVE.
• R&D Investments: Increased spending in R&D to support ongoing product development.

3. Forward Guidance and Outlook

• Q1 2026 Revenue Guidance: Expected between $9.6 million and $10.3 million, reflecting a 3% to 10% increase year-over-year.
• Full Year 2026 Revenue Growth: Preliminary estimate of 16% to 25% growth compared to 2025, with expectations for improved performance in the latter half of the year.
• Sales Cycle: Anticipated to be stretched due to industry adjustments but showing signs of improvement.

4. Bad News, Challenges, or Points of Concern

• CMS Reimbursement Changes: Significant reductions in reimbursement rates for skin substitutes have created pressure on the wound care market, affecting customer counts and growth rates.
• Customer Disruptions: Many wound care providers faced financial distress, leading to a higher number of discontinued UltraMIST systems.
• Sales Cycle Lengthening: The selling cycle has been extended due to uncertainty in the industry, particularly among larger healthcare providers.
• Inventory Management: Transitioning to a reseller model may lead to channel inventory issues, requiring careful management.

5. Notable Q&A Insights

• Sales Cycle Dynamics: The CEO noted that smaller practitioners tend to buy more rapidly, while larger institutions take longer to close deals.
• Active Systems Definition: The company revised its definition of active systems to better reflect actual usage, removing inactive systems from the count.
• Manufacturing Updates: Improvements in applicator pricing and progress on a new manufacturing line were discussed, with expectations for increased gross margins in the future.
• Market Interest: There is a notable increase in inbound interest from potential customers, indicating a positive shift in market dynamics despite current challenges.

Overall, SANUWAVE reported strong financial results for Q4 2025, but faces significant challenges due to industry-wide reimbursement changes and customer disruptions. The company is adapting its strategy to leverage new market opportunities while managing risks associated with its evolving sales model.